We are international
Donate
TEXT SIZE   


Characterization and preclinical evaluation of NKT cells in multiple myeloma
Eline Menu, PhD
Vrije Universiteit Brussel (VUB)
Brussels, Belgium
02.03.10

This grant is funded by Michael McKean in honor of Lee Grayson.

One strategy to target multiple myeloma is using a patient's immune system to target the tumor. However, myeloma cells can evade the immune system. Therefore, new drugs are being studied that can activate the immune system and enhance anti myeloma activity. In this project, Dr. Menu and colleagues will use the ST33MM mouse model to test a new activator of NKT (natural killer T-lymphocytes) cells preclinically. They will first characterize the NKT population in these mice and test their functionality against ST33MM cells and a CD1d transduced ST33MMvt cell line. They will then compare the efficiency of a new analogue in its capacity to activate NKT cells and reduce myeloma burden both in vitro and in vivo. This study will provide a potential new approach for immunotherapy in myeloma.


 related articles
Bone marrow microenvironment and multiple myeloma chemotherapy optimization
Development of the antihelmintic flubendazole as a novel therapeutic agent for the treatment of multiple myeloma
Mesenchymal cell cytotherapy for multiple myeloma
MMSET and epigenetic control in t(4;14) myelomas
Novel anti-myeloma therapy by targeting molecular signaling regulated by galectin family proteins
Reolysin: a novel reovirus-based therapy for multiple myeloma